Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All
i


Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013

Filetype[PDF-498.63 KB]


Details:
No Related Documents.

You May Also Like:

  1. Filetype[PDF - 576.47 KB]
    Personal Author:
    MacNeil, Jessica R. ; Medah, Isaïe ; ...
    Published Date:
    Mar 2014
    Source:
    Emerg Infect Dis. 20(3):394-399.
    Description:
    Multidrug- (MDR) and extensively drug-resistant tuberculosis (XDR TB) are commonly associated with Beijing strains. However, in KwaZulu-Natal, South A...
    File Type:
    Filetype[PDF - 576.47 KB]
    File Type:
    Filetype[PDF - 576.47 KB]
  2. Filetype[PDF - 576.47 KB]
    Personal Author:
    MacNeil, Jessica R. ; Medah, Isaïe ; ...
    Published Date:
    Mar 2014
    Source:
    Emerg Infect Dis. 20(3):394-399.
    Description:
    In 2010, Burkina Faso became the first country to introduce meningococcal serogroup A conjugate vaccine (PsA-TT). During 2012, Burkina Faso reported i...
    File Type:
    Filetype[PDF - 576.47 KB]
    File Type:
    Filetype[PDF - 576.47 KB]
  3. Filetype[PDF - 380.24 KB]
    Personal Author:
    Meyer, Sarah A. ; Kambou, Jean Ludovic ; ...
    Published Date:
    Jan 28 2015
    Source:
    Vaccine. 33(12):1492-1498.
    Description:
    BackgroundA new serogroup A meningococcal conjugate vaccine (PsA-TT, MenAfriVac™) has been developed to combat devastating serogroup A Neisseria men...
    File Type:
    Filetype[PDF - 380.24 KB]
    File Type:
    Filetype[PDF - 380.24 KB]
  4. Filetype[PDF - 171.94 KB]
    Personal Author:
    Terranella, Andrew ; Cohn, Amanda ; ...
    Published Date:
    Sep 21 2011
    Source:
    Infect Drug Resist. 2011; 4:161-169.
    Description:
    Meningococcal conjugate vaccines have several advantages over polysaccharide vaccines, including the ability to induce greater antibody persistence, a...
    File Type:
    Filetype[PDF - 171.94 KB]
    File Type:
    Filetype[PDF - 171.94 KB]
  5. Filetype[PDF - 188.66 KB]
    Personal Author:
    Massenet, D. ; Vohod, D. ; ...
    Published Date:
    Nov 2011
    Source:
    Emerg Infect Dis. 17(11):2070-2072.
    File Type:
    Filetype[PDF - 188.66 KB]
    File Type:
    Filetype[PDF - 188.66 KB]